DeepMed Research

Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients

Phase 4

Completed

Conditions: ASCVD

Interventions: Drug: Monorova
Drug: Rosuvamibe

First Posted Date: 2018-04-11

Last Posted Date: 2019-12-30

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 270

Registration Number: NCT03494270

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension

Phase 4

Completed

Conditions: Hypertension
ASCVD
Impaired Fasting Glucose

Interventions: Drug: Monorova® + Amlopin®
Drug: Duowell®

First Posted Date: 2018-03-22

Last Posted Date: 2021-06-02

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 100

Registration Number: NCT03474562

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Dankook University Hospital, Cheonan, Korea, Republic of
🇰🇷
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of

and more 1 locations

Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus
Hypercholesterolemia

Interventions: Drug: Rosuvamibe® Tab
Drug: Monorova® Tab

First Posted Date: 2018-02-26

Last Posted Date: 2019-07-23

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 140

Registration Number: NCT03446261

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia

Phase 4

Conditions: Alzheimer's Disease

Interventions: Drug: Alfoatirin® Tab. + Aripezil® Tab.
Drug: Aripezil® Tab.

First Posted Date: 2018-02-22

Last Posted Date: 2020-12-22

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 79

Registration Number: NCT03441516

Locations: 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷
Gyeongsang National University Hospital, Busan, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

and more 3 locations

High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes

Phase 4

Conditions: Type 2 Diabetes
Atherosclerotic Cardiovascular Disease

Interventions: Drug: Rosuvamibe
Drug: Monorova

First Posted Date: 2018-01-18

Last Posted Date: 2020-12-14

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 140

Registration Number: NCT03403556

Locations: 🇰🇷
Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
🇰🇷
The Catholic University of Korea, St. Vincent's Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of

and more 3 locations

A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients

Phase 4

Completed

Conditions: Respiratory Disease

Interventions: Drug: YMC026
Drug: Placebo

First Posted Date: 2017-11-07

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 223

Registration Number: NCT03334916

Locations: 🇰🇷
The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of

Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

Phase 4

Completed

Conditions: Dyslipidemia
Hypertension

Interventions: Drug: Telmisartan
Drug: Duowell®

First Posted Date: 2017-08-30

Last Posted Date: 2021-04-06

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 80

Registration Number: NCT03267329

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706

Phase 1

Completed

Conditions: Dyslipidemia
Type 2 Diabetes Mellitus

Interventions: Drug: YHR1705
Drug: YHR1706
Drug: YHR1705+YHR1706

First Posted Date: 2017-08-01

Last Posted Date: 2017-11-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 28

Registration Number: NCT03235362

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Anagre Cap. in Patients With High-Risk Essential Thrombocythemia

Phase 4

Completed

Conditions: Essential Thrombocythemia

Interventions: Drug: Anagre Cap.

First Posted Date: 2017-07-27

Last Posted Date: 2021-07-21

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 70

Registration Number: NCT03232177

Locations: 🇰🇷
Veterans Health Service medical Center, Seoul, Korea, Republic of
🇰🇷
Dongguk University Medical Center, Goyang, Korea, Republic of
🇰🇷
The Catholic University of Korea. ST. Vincents Hospital, Suwon-si, Gyeonggi, Korea, Republic of

and more 17 locations

A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia

Phase 4

Completed

Conditions: Diabetes Mellitus and Hypercholesterolemia

Interventions: Drug: Rosuvastatin
Drug: Rosuvastatin+Ezetimibe

First Posted Date: 2017-07-14

Last Posted Date: 2019-09-23

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 85

Registration Number: NCT03217409

Locations: 🇰🇷
Soon Chun Hyang University Hospital Bucheon, Gyeonggi-do, Korea, Republic of
🇰🇷
Soon Chun Hyang University Hospital Cheonan, Cheonan, Korea, Republic of
🇰🇷
Soon Chun Hyang University Hospital Seoul, Seoul, Korea, Republic of

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy